This inventor holds 4 USPTO granted patents. Top assignee: Pierre Fabre Medicament. Active years: 2000-2006.
Company Filing History:
Years Active: 2000-2006
Title: Bruno Legrand: Innovator in Medicinal Chemistry
Introduction
Bruno Legrand is a notable inventor based in Lautrec, France. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative patents. With a total of 4 patents, his work focuses on developing new pharmaceutical compounds that have the potential to improve health outcomes.
Latest Patents
One of his latest patents is titled "Benzoxathiepine derivatives and their use as medicines." This invention concerns 3-arylthio-propyl-amino-3,4-dihydro-2H-1,5-aryloxathiepin derivatives, which have various applications in medicine. The general formula includes specific radicals that can form carbon-containing cycles or oxygen-containing heterocycles, showcasing the complexity and potential of these compounds.
Another significant patent is "Substitute 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use." This invention involves compounds with a variety of functional groups, including alkyl radicals and halogens, which can be utilized in therapeutic applications. The detailed chemical structures and their possible hydrates highlight the innovative nature of his work.
Career Highlights
Bruno Legrand is associated with Pierre Fabre Medicament, a company known for its commitment to research and development in pharmaceuticals. His role in this organization has allowed him to focus on creating impactful medicinal products that address various health issues.
Collaborations
Throughout his career, Bruno has collaborated with esteemed colleagues such as Gareth W John and Jean-Pierre Rieu. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Bruno Legrand's contributions to medicinal chemistry through his innovative patents demonstrate his commitment to improving healthcare. His work continues to influence the pharmaceutical industry, paving the way for new therapeutic solutions.